Osmol-logo-blue-small-margins2.png
Osmol Therapeutics Appoints Ron Weitzman, M.D., as Interim Chief Medical Officer
04 mars 2024 08h00 HE | Osmol Therapeutics
Osmol Therapeutics Appoints Ron Weitzman, M.D., as Interim Chief Medical Officer
Immuneering-logo (1).png
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
04 mars 2024 08h00 HE | Immuneering Corporation
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for...
arvinas_logoART_lg.jpg
Arvinas to Participate in Upcoming Investor Conferences
04 mars 2024 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Immuneering-logo (1).png
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
01 mars 2024 08h00 HE | Immuneering Corporation
- Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 - - Dosing of first patient in the expanded Phase 2a portion of Phase 1/2a trial of IMM-1-104...
Cardiff.jpg
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
29 févr. 2024 16h06 HE | Cardiff Oncology, Inc.
- New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients - -...
Cardiff.jpg
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
29 févr. 2024 16h05 HE | Cardiff Oncology, Inc.
- Phase 2 trial in patients with RAS-mutated mCRC will evaluate onvansertib plus SoC versus SoC alone in the first-line setting - - Pfizer Ignite is responsible for the clinical execution of the...
AIMLogo.jpg
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
29 févr. 2024 08h45 HE | AIM ImmunoTech Inc.
Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen’s potential to address multiple high-value indications OCALA, Fla.,...
arvinas_logoART_lg.jpg
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
27 févr. 2024 07h00 HE | Arvinas Inc.
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the...
Transparency Market Research
Oncology Nutrition Market Poised to Grow to USD 3.6 billion by 2031, With a 6.2% CAGR: Exclusive Report by Transparency Market Research, Inc.
26 févr. 2024 20h02 HE | Transparency Market Research
Wilmington, Delaware, United States, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global oncology nutrition market was projected to attain US$ 2.1 billion in 2022. It is...
RM Primary Logo - Humble.png
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
26 févr. 2024 16h05 HE | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...